Clinical presentation of asymptomatic and symptomatic women who tested positive for genital gonorrhoea at a sexual health service in Melbourne, Australia

Mario Martín-Sánchez1,2, Christopher K. Fairley1,3, Jason J. Ong1,3, Kate Maddaford1, Marcus Y. Chen1,2, Deborah A. Williamson4, Catrina S. Bradshaw1,3 and Eric P.F. Chow1,3,5

1Melbourne Sexual Health Centre, Alfred Health, Melbourne, VIC, Australia; 2Preventive Medicine and Public Health Training Unit PSMar-UPF-ASPB, Barcelona, Spain; 3Central Clinical School, Monash University, Melbourne, VIC, Australia; 4Department of Microbiology and Immunology, Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia and 5Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia

Abstract
Gonorrhoea cases in women have been rising in Australia in the 2010s but the cause of the increase is not well understood. This cross-sectional study aimed to describe the characteristics of genital gonorrhoea infection in women attending the Melbourne Sexual Health Centre, Australia. Gonorrhoea cases were diagnosed by nucleic acid amplification test (NAAT) and/or culture. Genitourinary specimens were obtained in 12 869 clinic visits in women aged 16 years or above between August 2017 and August 2018. Genital gonorrhoea was detected in 142 (1.1%) of the visits. Almost half of the cases were asymptomatic, 47.9% [95% confidence interval (CI) 39.8–56.1%]; yellow, green or pus-like vaginal discharge was present in 11.3% (95% CI 7.0–17.6%) and other genital symptoms in 40.8% (95% CI 33.1–49.1%) of the cases. The mean time between last sexual contact and onset of symptoms was 7.3 days and between the onset of symptoms to presentation to the clinic was 12.1 days. Half of the cases of genital gonorrhoea among women are asymptomatic and these cases would have been missed by testing of only symptomatic women. Further epidemiological and behavioural research is required to understand the temporal changes in sexual practices among women in Australia.

1. Introduction
It is considered that the current epidemic of gonorrhoea mainly affects men, particularly gay, bisexual and other men who have sex with men (MSM) in Australia [1, 2]. Gonorrhoea is deemed to be uncommon among women in major Australian cities (<1% in the population); however rises have been observed in the 2010s [3–5]. This increase has also been reported among women in other high-income countries such as England, Spain or the USA [6–10]. The rise in gonorrhoea cases has also been observed in MSM and heterosexual men [11]. Overall, there was an 80% increase in the notification rate of gonorrhoea (from 65.5 to 118.0 per 100 000) between 2013 and 2017 in the total Australian population.

The reasons underlying the rise in gonorrhoea among women remain unclear. While the Australian Study of Health and Relationships surveys reported there was no change in condomless penile-vaginal sex nor in the number of sexual partners among women between 2001 and 2013 [12, 13], trend data on sexual practices among Australian women thereafter is scarce and other factors (e.g. sex overseas, use of smartphone dating applications) may have changed over time and contributed to the rise of gonorrhoea [3, 14–16]. Other reasons besides sexual practices may include sociodemographic changes or changes in health services use. The increase in health care demand from the rising rates of sexually transmitted infections (STIs) may be making it harder to access health care, and consequently increasing the duration of untreated infection which would lead to ongoing transmission [17–19].

Genital gonorrhoea can be asymptomatic in women and, hence individuals may not be aware of their infection for long periods. Untreated gonorrhoea in women can lead to pelvic inflammatory diseases and other serious complications including ectopic pregnancy or infertility [20], making prompt identification and treatment especially important. However, recent studies on genital gonorrhoea symptomatology in women are very limited and most studies were conducted in the 1970s and culture was used for gonorrhoea diagnosis in these studies [21–23].
Accordingly, the primary aim of this study was to estimate the proportion of genital gonorrhoea cases that were asymptomatic and symptomatic among women attending a sexual health clinic in Melbourne in Australia using nucleic acid amplification test (NAAT). The secondary aim was to describe the time from the last sexual contact to the onset of symptoms and the time to attend health care following the onset of symptoms to determine if these offered any insights into reasons for the recent increases in the infection rates and consequently, to potential public health interventions.

2. Methods

2.1 Study population

This was a cross-sectional study including all women aged 16 years or above attending the Melbourne Sexual Health Centre (MSHC), Australia, between August 2017 and August 2018. MSHC is a public HIV/STI clinic that offers a range of free clinical services regarding sexual health. MSHC is the largest sexual health clinic in Victoria and provides more than 50,000 clinical consultations a year. For the purposes of this study, only cisgender women were included.

Prior to August 2017, as genital gonorrhoea was considered very uncommon in female attendees, testing was only recommended among women who reported genital symptoms (i.e. presence of discharge or dysuria) or sexual contact with someone diagnosed with gonorrhoea infection as per the Australian STI Management Guidelines [24]. However, MSHC implemented an in-house screening policy in August 2017, and all women attending MSHC, regardless of the presence of symptoms, were offered genital gonorrhoea and chlamydia screening by NAAT using Aptima Combo (AC2) assay (Hologic Panther system; Hologic, San Diego, CA, USA) [25, 26]. All clients attending MSHC were asked if they had any symptoms by the triage nurse and then by the treating clinician. Symptomatic women were examined by the clinician and an endocervical swab was obtained for NAAT and/or culture for *Neisseria gonorrhoeae*. No examination was performed among asymptomatic women [27], but they were asked to self-collect a vaginal swab or first pass urine (FPU) and the specimens were tested by NAAT for *N. gonorrhoeae*. If a swab was collected for culture, it was plated immediately onto modified Thayer-Martin medium for gonorrhoea culture and a smear prepared for Gram stain and microscopy to look for Gram negative diplococci. For individuals who tested positive by NAAT but had no culture performed at the screening visit, a culture test was performed on the subsequent visit before gonorrhoea treatment was administered, to determine the antimicrobial susceptibility profile.

![Fig. 1. Investigations performed in 142 cases of genital N. gonorrhoeae infection among women attending MSHC, 2017–2018.](https://doi.org/10.1017/S0950268820002265) Published online by Cambridge University Press

<table>
<thead>
<tr>
<th>142 specimens</th>
<th>45 NAAT on the first visit + culture*</th>
<th>36 positive cultures (80.0%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>97 NAAT on the first visit?</td>
<td>74 culture performed at MSHC on a subsequent visit</td>
<td></td>
</tr>
<tr>
<td>56 negative cultures*</td>
<td>18 positive cultures* (24.3%)</td>
<td></td>
</tr>
</tbody>
</table>

*33 (73.3%) cases were symptomatic, including eight cases with yellow, green or pus-like vaginal discharge, 12 (26.7%) were asymptomatic.

1In four cases only culture was performed as it was previously diagnosed outside MSHC.

2Of the 56 cases with a negative culture in a subsequent visit, 10 (17.9%) had received antibiotic treatment on the first visit (five received treatment for bacterial vaginosis, two for urinary tract infection, two for chlamydia and one for both chlamydia and bacterial vaginosis); among the ones with positive cultures, four (22.2%) had received antibiotic treatment (three for bacterial vaginosis and one for urinary tract infection).
Table 1. Demographic and sexual behaviour characteristics of 142 cases of genital *N. gonorrhoeae* infection among women attending MSHC, 2017–2018

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All women (N = 142)</th>
<th>Symptomatic women (N = 74)</th>
<th>Asymptomatic women (N = 68)</th>
<th>P value&lt;sup&gt;‡&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>28 (24–34)</td>
<td>27 (24–33)</td>
<td>29 (24–36)</td>
<td>0.323</td>
</tr>
<tr>
<td>Age (years), n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.556</td>
</tr>
<tr>
<td>16–25</td>
<td>55 (38.7)</td>
<td>30 (40.5)</td>
<td>25 (36.8)</td>
<td>0.556</td>
</tr>
<tr>
<td>26–35</td>
<td>57 (40.1)</td>
<td>31 (41.9)</td>
<td>26 (38.2)</td>
<td></td>
</tr>
<tr>
<td>≥36</td>
<td>30 (21.1)</td>
<td>13 (17.6)</td>
<td>17 (25.0)</td>
<td></td>
</tr>
<tr>
<td>Country of birth, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.722</td>
</tr>
<tr>
<td>Australia</td>
<td>55 (38.7)</td>
<td>31 (41.9)</td>
<td>24 (35.3)</td>
<td>0.722</td>
</tr>
<tr>
<td>Overseas</td>
<td>79 (55.6)</td>
<td>39 (52.7)</td>
<td>40 (58.8)</td>
<td></td>
</tr>
<tr>
<td>No information</td>
<td>8 (5.6)</td>
<td>4 (5.4)</td>
<td>4 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Indigenous status, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.206</td>
</tr>
<tr>
<td>Indigenous origin</td>
<td>2 (1.4)</td>
<td>2 (2.7)</td>
<td>0 (0)</td>
<td>0.206</td>
</tr>
<tr>
<td>Non-indigenous origin</td>
<td>103 (72.5)</td>
<td>50 (67.6)</td>
<td>53 (77.9)</td>
<td></td>
</tr>
<tr>
<td>No information</td>
<td>37 (26.1)</td>
<td>22 (29.7)</td>
<td>15 (22.1)</td>
<td></td>
</tr>
<tr>
<td>Number of male sexual partners in the preceding 3 months, median (IQR)&lt;sup&gt;‡&lt;/sup&gt;</td>
<td>2 (1–4)</td>
<td>2 (1–3)</td>
<td>2 (1–5)</td>
<td>0.965</td>
</tr>
<tr>
<td>Number of male sexual partners in the preceding 3 months, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.082</td>
</tr>
<tr>
<td>≤4</td>
<td>82 (57.7)</td>
<td>49 (66.2)</td>
<td>33 (48.5)</td>
<td>0.082</td>
</tr>
<tr>
<td>&gt;4</td>
<td>21 (14.8)</td>
<td>10 (13.5)</td>
<td>11 (16.2)</td>
<td></td>
</tr>
<tr>
<td>No information</td>
<td>39 (27.5)</td>
<td>15 (20.3)</td>
<td>24 (35.3)</td>
<td></td>
</tr>
<tr>
<td>Had a female sexual partner(s) in the preceding 3 months, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.550</td>
</tr>
<tr>
<td>Yes</td>
<td>12 (8.5)</td>
<td>5 (6.8)</td>
<td>7 (10.3)</td>
<td>0.550</td>
</tr>
<tr>
<td>No</td>
<td>104 (73.2)</td>
<td>57 (77.0)</td>
<td>47 (69.1)</td>
<td></td>
</tr>
<tr>
<td>Not information</td>
<td>26 (18.3)</td>
<td>12 (16.2)</td>
<td>14 (20.6)</td>
<td></td>
</tr>
<tr>
<td>Condom use with male sexual partners in the preceding 3 months, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.205</td>
</tr>
<tr>
<td>Always</td>
<td>12 (8.5)</td>
<td>5 (6.8)</td>
<td>7 (10.3)</td>
<td>0.205</td>
</tr>
<tr>
<td>Not always&lt;sup&gt;‡&lt;/sup&gt;</td>
<td>88 (62.0)</td>
<td>51 (68.9)</td>
<td>37 (54.4)</td>
<td></td>
</tr>
<tr>
<td>No information</td>
<td>42 (29.6)</td>
<td>18 (24.3)</td>
<td>24 (35.3)</td>
<td></td>
</tr>
<tr>
<td>Sexual contact with a man diagnosed with gonorrhoea, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.650</td>
</tr>
<tr>
<td>Yes</td>
<td>25 (17.6)</td>
<td>12 (16.2)</td>
<td>13 (19.1)</td>
<td>0.650</td>
</tr>
<tr>
<td>No</td>
<td>117 (82.4)</td>
<td>62 (83.8)</td>
<td>55 (80.9)</td>
<td></td>
</tr>
<tr>
<td>Current sex worker, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.011</td>
</tr>
<tr>
<td>Yes</td>
<td>52 (36.6)</td>
<td>19 (25.7)</td>
<td>33 (48.5)</td>
<td>0.011</td>
</tr>
<tr>
<td>No</td>
<td>83 (58.5)</td>
<td>52 (70.3)</td>
<td>31 (45.6)</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Asymptomatic cases were women who reported no genitourinary symptoms on the day of testing.

2.3 Data analysis

Descriptive analyses were conducted to summarise the key parameters. The 95% confidence intervals (CIs) for the sample proportions were calculated using Agresti-Coull (adjusted Wald) method. All analyses were conducted using SPSS (version 25, Armonk, NY: IBM Corp). Ethical approval was granted by the Alfred Hospital Ethics Committee, Melbourne, Australia (450/18).

3. Results

There were 17 258 clinic visits by 9302 individual women attending MSHC during the study period. Genitourinary specimens were obtained (FPU, endocervical or vaginal specimens) in 12 869 (74.6%) clinic visits from 7350 individual women. Genital gonorrhoea was detected in 1.1% (142/12 869) of the clinic visits where women were tested for genital gonorrhoea, corresponding to 142 different gonorrhoea cases in 140 individual women. The investigations performed including NAAT and culture for *N. gonorrhoeae* are shown in Figure 1. The median age of the 142 genital gonorrhoea cases was 28 years [interquartile range (IQR) 24–34], 79 (55.6%) were born overseas and 13 (9.2%) had a previous gonorrhoea diagnosis at the MSHC. The median number of male sexual partners in the preceding three months was 2 (IQR 1–4) and 12 (8.5%) reported having a female sexual partner in the preceding three months. Only 12 (8.5%) reported always using condoms with male partners for sex in the preceding three months, 37 (26.1%) reported having sex overseas in the preceding 12 months and 52 (36.6%) were currently working as sex workers (Table 1).

Almost half of the cases (*n* = 68, 47.9%, 95% CI 39.8–56.1%) reported no symptoms (Table 2). Of the 74 cases (52.1%, 95% CI 44.0–60.1%) where women reported any symptom, the most common symptoms reported included a clear abnormal vaginal discharge (*n* = 29, 39.2%), dysuria (*n* = 23, 31.1%) and a change in vaginal discharge to a yellow, green or pus-like vaginal discharge (*n* = 16, 21.6%; 11.3% [95% CI 7.0–17.6%] over the total number of cases). A smaller proportion also reported Per Vaginal (PV)/postcoital bleeding (*n* = 9; 12.2%) and pelvic pain (*n* = 8; 10.8%) (Table 3). Among the 142 genital gonorrhoea cases, 18 (12.7%) had concurrent bacterial vaginosis and 11 (7.7%) had pelvic inflammatory disease. Of the 25 (17.6%) cases with sexual contact with a male diagnosed with gonorrhoea, 13 (52.0%) were asymptomatic, and 12 (48.0%) symptomatic, including three cases with yellow, green or pus-like vaginal discharge.

There were 10 symptomatic women who reported the date of last sexual contact, and the mean time between last sexual contact and the onset of symptoms was 7.3 days [standard deviation (SD) 4.4, ranging from 2 to 16 days]. In addition, there were 60 symptomatic women who reported the date of symptom onset, and the mean time between the onset of symptoms and presentation to the clinic was 12.1 days (SD 14.6, ranging from 1 to 90 days) (Table 2). Among these 60 symptomatic women, 22 (36.7%) presented to the clinic up to 5 days after symptoms onset, 16 (26.7%) between 6 and 10 days and 22 (36.7%) after 10 days or more.

Of the 142 cases with genital gonorrhoea, 135 were also tested for genital chlamydia and 18 (13.3%) tested positive for genital chlamydia by NAAT. Among 68 asymptomatic cases, the positivity for genital chlamydia was 13.6% and among symptomatic was 13.0% (Table 2).
4. Discussion

In this clinical audit of 142 confirmed genital gonorrhoea cases in women attending a sexual health clinic in Melbourne, we found that 48% of the cases among women did not have any reported genital symptoms on the day of testing, and only an 11% had typical *N. gonorrhoeae* discharge (i.e. yellow, green or pus-like vaginal discharge). This suggests that a substantial proportion of asymptomatic cases would have been missed without screening of asymptomatic women. This result also contrasts with heterosexual men where more than 90% of genital cases are symptomatic [28]. Along similar lines, time from symptoms onset to presentation to the clinic was of 12 days, which could be partially explained by the non-specific symptoms of gonorrhoea. Given the importance of the early detection of infectious cases for effective gonorrhoea control, it is possible that a public health campaign aimed at increasing awareness and knowledge on gonorrhoea, as well as, improving testing of gonorrhoea in symptomatic women and asymptomatic women at risk may be indicated.

There are some limitations in the study that should be noted. First, this study was conducted in one urban major public sexual health clinic in Melbourne that sees only 25% of the cases of gonorrhoea diagnosed in women. Our data may therefore not be representative of presentations to general practice [29]. Women in our study may be biased towards those with genital symptoms or contacts of infection. Besides that, sex workers may be overrepresented in our study for the mandatory three-monthly HIV/STI screening [30]. Second, recall bias might have occurred when women reported the time between the onset of symptoms and last sexual contact. Moreover, a substantial proportion of data was missing because it was not always systematically collected, hence we could only present the results of the time between last sexual contact and the onset of symptoms when the data is available. Third, sexual health services in Melbourne are quite limited and it is not always possible to see all individuals on the day that they present symptoms [17]. This could have contributed to more than five days elapsed since symptoms onset to presentation to the clinic in almost two-thirds of the cases. It is therefore possible that the time between the onset of symptoms and presentation may be longer in our study than for women attending other services.

There have been very limited studies estimating the proportion of gonorrhoea in women that is asymptomatic and most of these studies were conducted in the 1970s. Asymptomatic screening in women is not currently recommended in many countries such as the USA and UK. In addition, clinical diagnosis of gonorrhoea in symptomatic women is always difficult because the presence of

<table>
<thead>
<tr>
<th>Table 2. Clinical characteristics of cases of genital <em>N. gonorrhoeae</em> infection among women attending MSHC, 2017–2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
</tr>
<tr>
<td>History</td>
</tr>
<tr>
<td>Genital symptoms reported on day of test</td>
</tr>
<tr>
<td>Symptomatic</td>
</tr>
<tr>
<td>Days between last sexual contact and onset of symptoms, N, mean (SD)</td>
</tr>
<tr>
<td>Days between onset of symptoms and presentation to the clinic, N, mean (SD)</td>
</tr>
<tr>
<td>Asymptomatic</td>
</tr>
<tr>
<td>Investigations†</td>
</tr>
<tr>
<td>Gonorrhoea culture positive from genital swab</td>
</tr>
<tr>
<td>Symptomatic</td>
</tr>
<tr>
<td>Asymptomatic</td>
</tr>
<tr>
<td>Tested positive for genital chlamydia</td>
</tr>
<tr>
<td>Symptomatic</td>
</tr>
<tr>
<td>Asymptomatic</td>
</tr>
</tbody>
</table>

CI, confidence interval; SD, standard deviation; NAAT, nucleic acid amplification test.

*10 and 60 women reported date of last sexual contact and date of onset of symptoms, respectively. †The denominator of the percentage is the total of specimens in which the investigation was performed.

<table>
<thead>
<tr>
<th>Table 3. Symptoms present on the day of testing among 74 symptomatic cases of genital <em>N. gonorrhoeae</em> infection among women attending MSHC, 2017–2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms*</td>
</tr>
<tr>
<td>Clear abnormal vaginal discharge</td>
</tr>
<tr>
<td>Dysuria</td>
</tr>
<tr>
<td>Yellow, green or pus-like vaginal discharge</td>
</tr>
<tr>
<td>Urinary frequency/nocturia</td>
</tr>
<tr>
<td>Vaginal odour</td>
</tr>
<tr>
<td>Dyspareunia</td>
</tr>
<tr>
<td>PV bleeding/postcoital bleed</td>
</tr>
<tr>
<td>Vulvar redness</td>
</tr>
<tr>
<td>Vulvar itch</td>
</tr>
<tr>
<td>Hematuria</td>
</tr>
<tr>
<td>Genital ulcer</td>
</tr>
<tr>
<td>Vulvar pain</td>
</tr>
<tr>
<td>Vaginal itch</td>
</tr>
<tr>
<td>Urethral discomfort</td>
</tr>
<tr>
<td>Vaginal pain</td>
</tr>
<tr>
<td>Perineal pain</td>
</tr>
</tbody>
</table>

*There were cases in which more than one symptom was present
non-specific symptoms (e.g. dysuria, dyspareunia, vulvar itch or pelvic pain) may be confounded by other infections such as bacterial vaginosis, Chlamydia trachomatis and Trichomonas vaginalis. In our study, we found that 48% of women who tested positive for N. gonorrhoeae did not report any genital symptoms on the day of screening. However, McCormack and colleagues reviewed 278 women with gonorrhoea in 1974 in Boston in a hospital setting and they found that only 19% of the cases were asymptomatic [31]. Furthermore, we found that 52% (13/25) of gonorrhoea contacts that tested positive for genital gonorrhoea were asymptomatic. Our previous audit in 2017–18 showed 44% (26/59) of asymptomatic female gonorrhoea contacts tested positive by NAAT at the genital site [32]. However, Pariser and colleagues (1968) found that only 29% of asymptomatic female gonorrhoea contacts were culture-positive for gonorrhoea [33]. The low positivity in Pariser and colleagues’ study may be due to poor sensitivity in culture compared to NAAT. Past studies have shown that the majority of women with gonorrhoea would develop symptoms within 9–11 days after sexual exposure and this is similar to the estimate of 7.3 days in our study [22, 23].

The increase in the rates of gonorrhoea among women in Australia has happened alongside an increase in the incidence of chlamydia and infectious syphilis since the mid-2010s [2, 34, 35]. This has also led to the re-emergence of congenital syphilis in Victoria in 2017, which has not emerged in the state since 2004 [34, 35]. The Australian national surveys have revealed that there were no significant changes in the number of partners and condomless sex among women in Australia between 2001 and 2013 [11, 12]; however, the much of the STI rise occurs after 2013, and there have been very limited behavioural studies examining sexual practices among women in Australia. The rises in gonorrhoea in women in Australia remain unclear and it may be due to other unmeasured factors (e.g. group sex, use of smartphone dating applications, transmission from higher-incidence populations) that may have changed over time. Nevertheless, given the importance of access to health care for the control of STIs, public health campaigns and sexual health educations are important to increase the awareness and recognition of STI-related symptoms. General practitioners should also be informed and trained accordingly to increase the knowledge and awareness of the current STI epidemic, testing and treatment guidelines.

In conclusion, genital gonorrhoea is largely asymptomatic or has an unspecific clinical presentation among women. Testing only women with typical N. gonorrhoeae discharge would have missed a considerable number of cases. Further efforts must be made to promote gonorrhoea screening at primary care settings in Victoria, including training on test and treat among general practitioners. Additionally, epidemiological and behavioural research is required to understand the temporal changes in sexual practices among women in Australia and how this could be related to recent increases in the incidence of gonorrhoea.

Acknowledgements. The authors acknowledge Afrizal Afrizal for his assistance with data extraction at the Melbourne Sexual Health Centre.

Funding. CKF and CSB are supported by an Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grant (GNT172900 and GNT173361, respectively). DAW and EPFC are supported by an Australian NHMRC Emerging Leadership Investigator Grant (GNT174555 and GNT172873, respectively).

Conflicts of interest/Competing interests. The authors declare that they have no conflict of interest.

Ethics approval. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Alfred Hospital Ethics Committee, Melbourne, Australia (450/18). This study was an analysis of retrospective data collected from a clinical service. Informed consent is not required as per the ethical approval of this study.

Data Availability Statement. All relevant data generated or analysed during this study are included in this published article.

References